Cardiac Complications in Patients with COVID-19: An Integrative Literature Review
DOI:
https://doi.org/10.5294/aqui.2020.20.4.3Keywords:
Coronavirus infections, hospital care, cardiology, critical care, nursing care.Abstract
Complicaciones cardíacas en pacientes con covid-19: revisión integrativa de la literatura
Complicações cardíacas em pacientes com covid-19: revisão integrativa da literatura
Objective: To verify, based on the literature, what the main cardiac complications are in patients with COVID-19, during treatment in a hospital unit.
Materials and methods: An integrative review, carried out by searching for studies in eight national and international databases. The final sample consisted of 16 studies published between January and May 2020, which were subjected to structural evaluation by the following instruments: Case Report Guidelines, for case reports; and Strengthening the Reporting of Observational Studies in Epidemiology, for observational studies.
Results: The main cardiac complications were predominantly obstructive events, herein understood as acute myocardial infarction, followed by severe arrhythmic conditions and heart failure, all due to the hyperinflammation condition resulting from viral infection.
Conclusions: The knowledge about cardiac complications during COVID-19 treatment has become important, since it can collaborate for the adoption of more effective treatment protocols and guide the assistance offered by health professionals, in order to identify such complications and intervene early.
To reference this article / Para citar este artigo / Para citar este artículo
Maier SRO, Rodrigues JPF, Sudré MRS, Dessotte CAM. Cardiac Complications in Patients with COVID-19: An Integrative Literature Review. Aquichan. 2020;20(4):e2043. DOI: https://doi.org/10.5294/aqui.2020.20.4.3
Recibido: 18/08/2020
Aceptado: 25/09/2020
Publicado: 04/12/2020
Downloads
References
Lei S, Jiang F, Sua W, Chend C, Chene J, Meif W et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. E Clinical Medicine. 2020;21:e100331. Available from: https://doi.org/10.1016/j.eclinm.2020.100331
Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al. Cardiovascular implications of fatal outcomes of patients with Coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;27:e201017. Available from: https://doi.org/10.1001/jamacardio.2020.1017
Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019; 17:181-92. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097006/
World Health Organization. Pneumonia of unknown cause-China. 2020. Available from: https://www.who.int/csr/don/05-april-2020-pneumonia-of-unkown-cause-china/en/
World Health Organization. Novel coronavirus-China. 2020. Available from: https://www.who.int/csr/don/12-april-2020-novel-coronavirus-china/en/
Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12(2):e135. Available from: https://doi.org/10.3390/v12020135
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199-207. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121484/
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(1):507-13. DOI: https://doi.org/10.1016/S0140-6736(20)30211-7
Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M et al. Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial. Int J Antimicrob Agents. 2020;e105949 Available from: https://doi.org/10.1016/j.ijantimicag.2020.105949
Million M, Lagier J-C, Gautret P, Colson P, Fournier P-E, Amrane S et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Medicine and Infectious Disease. 2020;35:e101738. Available from: https://doi.org/10.1016/j.tmaid.2020.101738
Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc in exploratory COVID-19 (Coronavirus Disease 2019) Treatment. Circulation. 2020;141:e906-7. DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.047521
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159299/
Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D et al. Cardiac involvement in a patient with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):819-24. DOI: https://doi.org/10.1001/jamacardio.2020.1096
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: A retrospective cohort study. The Lancet. 2020;395:1054-62. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang Z et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA Cardiol. 2020;323(11):10619. DOI: https://doi.org/10.1001/jama.2020.1585
Zeng J, Liu Y, Yuan J, Wang F, Wu W, Li J et al. First case of COVID‑19 complicated with fulminant myocarditis: A case report and insights. Infection. 2020;10(ahead of print):1-5. DOI: https://doi.org/10.1007/s15010-020-01424-5
Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;e200950. DOI: https://doi.org/10.1001/jamacardio.2020.0950
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. DOI: https://doi.org/10.1016/S2213-2600(20)30116-8
Mendes KDS, Silveira RCCP, Galvão CM. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto Contexto Enferm. 2008;17(4):758-64. DOI: https://dx.doi.org/10.1590/S0104-07072008000400018
Mendes KDS, Silveira RCCP, Galvão CM. Uso de gerenciador de referências bibliográficas na seleção dos estudos primários em revisão integrativa. Texto Contexto Enferm. 2019; 28:e20170204. DOI: https://dx.doi.org/10.1590/1980-265X-TCE-2017-0204
Melnyk BM, Fineout-Overholt E. Making the case for evidence based practice. Melnyk BM, Fineout-Overholt E, organizadores. Evidence based practice in nursing & health care. A guide to best practice. Philadelphia (US): Lippincot Williams & Wilkins; 2005. p. 3-24.
Santos CMC, Pimenta CAM, Nobre MRC. The PICO strategy for the research question construction and evidence search. Rev Latino-am Enfermagem. 2007;15(3):508-11. Available from: http://www.scielo.br/pdf/rlae/v15n3/v15n3a23.pdf
Simera I, Altman DG, Moher D, Schulz KF, Hoey J. Guidelines for Reporting Health Research: The EQUATOR Network’s Survey of Guideline Authors. PLoS Med. 2008;5(6): e139. DOI: https://doi.org/10.1371/journal.pmed.0050139
Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. STROBE Initiative. J Clin Epidemiol. 2008;61(4):344-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18313558
Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: Consensus-based clinical case reporting guideline development. Headache. 2013;53(10):1541-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24266334
Moher D, Shamseer L, Clarke M, Ghersi D, Liberrati A, Petticrew M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Bio Med Central. 2015;4(1):1-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25554246
Aromataris E, Munn Z. Chapter 1: JBI Systematic Reviews. In: Aromataris E, Munn Z, editores. JBI Reviewer’s Manual. JBI; 2017. DOI: https://doi.org/10.46658/JBIRM-17-01
Inciardi RM, Adamo M, Lupi L, Cani DS, Pasquale MD, Tomasoni D et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. European Heart Journal. 2020;41:1821-9. DOI: https://doi.org/10.1093/eurheartj/ehaa388
Li M, Dong Y, Wang H, Guo W, Zhou H, Zhang Z et al. Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19. Nutrition, Metabolism & Cardiovascular Diseases. 2020;30(7):1061-7. DOI: https://doi.org/10.1016/j.numecd.2020.04.013
Xiong F, Tang H, Liu L, Tu C, Tian JB, Lei CT et al. Clinical characteristics of and medical interventions for COVID-19 in hemodialysis patients in Wuhan, China. JASN. 2020; ASN.2020030354. DOI: https://doi.org/10.1681/ASN.2020030354
Zhang J, Lu S, Wang X, Jia X, Li J, Lei H et al. Do underlying cardiovascular diseases have any impact on hospitalised patients with COVID-19? Heart. 2020;106:1119-21. DOI: http://dx.doi.org/10.1136/heartjnl-2020-317110
Zhen Y, Xua H, Yanga M, Zenga Y, Chena H, Liu R et al. Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu. Journal of Clinical Virology. 2020;127:104366. DOI: https://doi.org/10.1016/j.jcv.2020.104366
Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. Journal of Medical Virology. 2020;92(7):797-806. Available from: https://pubmed.ncbi.nlm.nih.gov/32198776/
Rothstein ES, Welch TD, Andrus BW, Jayne JE. Management of a patient presenting with anterior STEMI with concomitant COVID-19 infection early in the course of the U.S. pandemic. Catheter Cardiovasc Interv. 2020;1-6. DOI: https://doi.org/10.1002/ccd.28967
Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system. JAMA Cardiol. 2020;5(7):831-40. DOI: https://doi:10.1001/jamacardio.2020.1286
Ferguson J, Rosser JI, Quintero O, Scott J, Subramanian A, Gumma M et al. Characteristics and outcomes of coronavirus disease patients under nonsurge conditions, northern California, USA, March-April 2020. Emerg Infect Dis. 2020;26(8):1679-85. DOI: https://doi.org/10.3201/eid2608.201776
Bonow RO, Fonarow GC, O’Gara PT, Yancy CW. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol. 2020;5(7):751-3. DOI: http://doi.org/10.1001/jamacardio.2020.1105
Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020,27(7):E1-9. DOI: https://doi.org/10.1001/jamacardio.2020.3557
Ferrari F. COVID-19: dados atualizados e sua relação com o sistema cardiovascular. Arq Bras Cardiol. 2020;114(5):823-6. DOI: https://doi.org/10.36660/abc.20200215
Askin L, Tanrıverdi O, Askin H S. O efeito da doença de coronavírus 2019 nas doenças cardiovasculares. Arq Bras Cardiol. 2020;114(5):817-22. DOI: https://doi.org/10.36660/abc.20200273
Pacileo M, Giallauria F, Savarese C, Cirillo T, Crescibene F, Lorenzo AD et al. The role of echocardiography in SARS-CoV-2 pandemic: A compromise among appropriateness, safety and clinical impact. Monaldi Archives for Chest Disease. 2020;90:1358. Available from: https://www.monaldi-archives.org/index.php/macd/article/view/1358/1028
Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020;63(3):390-1. DOI: https://doi.org/10.1016/j.pcad.2020.03.001
Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B et al. ST-Segment elevation in patients with Covid-19 — A case series. N Engl J Med. 2020;382:2478-80. DOI: https://doi.org/10.1056/NEJMc2009020
Wei-jie G, Zheng-yi N, Yu H, Wen-hua L, Chun-quan O, Jian-xing H et al. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. Available from: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2002032
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-9. DOI: https://doi.org/10.1111/jth.14817
Liu Z, Xue XB, Zhi XZ. The epidemiological characteristics of an outbreak of 2019 novel Coronavirus Diseases (COVID-19) in China. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. 2020;41(2):145-51. Available from: https://pubmed.ncbi.nlm.nih.gov/32064853/
Strabelli TMV, Uip DE. Covid-19 e o coração. Arq Bras Cardiol. 2020; 114(4):598-600. DOI: http://dx.doi.org/10.36660/abc.20200209
Wang T, Du Z, Zhu F, Cao Z, An Z, Gao Y et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. 2020;395(10228):e52. DOI: https://doi.org/10.1016/S0140-6736(20)30558-4
Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diab Res Care. 2020;8:e001343. Available from: https://drc.bmj.com/content/8/1/e001343
Sama IE, Ravena A, Santema BT, Goor HV, Maaten JM, Cleland JGF et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. European Heart Journal. 2020;41:1810-7. Available from: https://academic.oup.com/eurheartj/article/41/19/1810/5834647
Gemes K, Talback M, Modig K, Ahlbom A, Berglund A, Feychting M et al. Burden and prevalence of prognostic factors for severe COVID‑19 in Sweden. European Journal of Epidemiology. 2020; 35:401-9. DOI: https://doi.org/10.1007/s10654-020-00646-z
Abajo FJ, Rodriguez-Martin S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: A case-population study. Lancet. 2020;395(1):1705-14. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31030-8/fulltext
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Aquichan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. Proposed Policy for Journals That Offer Open Access
Authors who publish with this journal agree to the following terms:
- The journal and its papers are published with the Creative Commons License Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). You are free to share copy and redistribute the material in any medium or format if you: give appropriate credit, provide a link to the license, and indicate if changes were made; don’t use our material for commercial purposes; don’t remix, transform, or build upon the material.
